One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
Version of Record online: 23 NOV 2012
© 2012 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 2, pages 204–213, January 2013
How to Cite
Sandborn, W. J., Colombel, J.-F., D'Haens, G., Van Assche, G., Wolf, D., Kron, M., Lazar, A., Robinson, A. M., Yang, M., Chao, J. D. and Thakkar, R. (2013), One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Alimentary Pharmacology & Therapeutics, 37: 204–213. doi: 10.1111/apt.12145
- Issue online: 17 DEC 2012
- Version of Record online: 23 NOV 2012
- Manuscript Accepted: 27 OCT 2012
- Manuscript Revised: 26 OCT 2012
- Manuscript Revised: 3 OCT 2012
- Manuscript Received: 26 SEP 2012
Table S1. Remission or response at week 52 for patients who did not respond to adalimumab at week 8 by either full or partial Mayo score (NRI and mNRI).
Table S2. Adalimumab week 8 responders (per full Mayo score), overall and by prior anti-TNF exposure (NRI and mNRI): clinical remission and clinical response (per full Mayo score) and mucosal healing at week 52; steroid-free remission or steroid discontinuation at week 52 (patients with baseline steroid use).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.